According to a Novo Nordisk announcement the results from their LEAD™ 6 extension study show that switching to once-daily Victoza® (Liraglutide [rDNA Origin] Injection) from exenatide improves blood sugar control in patients with type 2 diabetes.
The study published online in Diabetes Care evaluated the efficacy and safety of switching from exenatide, which is taken twice a day, to once-daily Victoza®. The results showed that patients who switched to the Victoza had improved A1C levels, a further reduction in fasting plasma glucose, body weight and systolic blood pressure.
